Synagis intramuscular injection 100mg, from AstraZeneca, contains palivizumab (genetical recombination) and is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. The standard is 100mg 1mL 1 bottle, YJ code 6250404A2026.
Synagis intramuscular injection 100mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →